Catch Bio

Cover Block

Field	Value
Name	Catch Bio
Tagline	Maps cancer risk factors and builds personalized screening protocols and action plans
Headquarters	Chicago, Illinois
Founded	2023
Stage	Seed
Business Model	B2C
Industry	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Funding Label	Seed
Total Disclosed	~$2,000,000

Links

• Website: https://app-dev.catchbio.com/

The Short Version

Catch Bio is a Chicago-based seed-stage healthtech company building a consumer platform that quantifies an individual's lifetime cancer risk and translates that risk into a personalized screening protocol and prevention plan [Crunchbase] [Kahn Longevity Center]. The company was incorporated in 2023 and raised approximately $2.0 million in an equity round filed in January 2025 [formds.com, Jan 2025]. Its product positioning sits at the intersection of the consumerization of preventive medicine and the growing willingness of self-pay patients to fund screening outside standard insurance pathways [f4.fund]. The company's pitch is to map risk factors across every major cancer and convert that map into an actionable plan covering screening cadence, biomarker tests, and behavior changes [Crunchbase] [f4.fund]. Over the next 12 to 18 months, the items worth tracking are: a named clinical or longevity-clinic distribution partner, evidence of paid user cohorts, and any disclosure around the medical advisory bench that underwrites its risk model.

Data Accuracy: YELLOW -- Founding year and seed amount corroborated across PitchBook, Crunchbase, and formds.com; product claims rely on company-adjacent writeups rather than independent press.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2C
Industry / Vertical	Healthtech, cancer prevention
Technology Type	Biotech / Life Sciences, risk-modeling software
Geography	North America (HQ Chicago, IL)
Growth Profile	Venture Scale
Funding	~$2.0M seed (Jan 2025) [formds.com, Jan 2025]

The Company in Brief

Catch Bio was founded in 2023 and is headquartered in Chicago, Illinois [PitchBook]. The company operates under the legal entity Catch Bio, Inc. [formds.com, Jan 2025]. Beyond the entity name, founding year, and a seed-stage equity raise of approximately $2,000,000 dated January 10, 2025, the company has left a light public footprint: there is no press release archive, and the product site resolves to a development subdomain [Catch Bio] [Crunchbase].

A writeup from the Kahn Longevity Center, a Detroit-area integrative cardiology clinic, positioned Catch as "the first platform to quantify your lifetime cancer risk and turn it into an actionable, personalized prevention strategy," suggesting at least one clinical channel partner or champion has engaged with the product [Kahn Longevity Center]. The seed equity filing in January 2025 marks the only confirmed financing event [formds.com, Jan 2025].

Data Accuracy: YELLOW -- Entity, HQ, and founding year confirmed by PitchBook and the SEC-style filing on formds.com; milestone narrative limited by the absence of independent press coverage.

What They Have Built

The product is a personalized cancer risk assessment service. Crunchbase summarizes it as a platform that "maps risk factors for every major cancer and builds an optimal screening protocol and personalized action plan" [Crunchbase]. The f4.fund profile describes a "comprehensive cancer risk assessment service that evaluates individual risk factors and biomarkers to help users understand and reduce their cancer risk through personalized action plans" [f4.fund]. The Kahn Longevity Center describes the output as a quantified lifetime cancer risk paired with an actionable, personalized prevention strategy [Kahn Longevity Center]. The product appears to combine three components: an intake that captures family history, lifestyle, and biomarker inputs; a risk model that scores lifetime cancer risk; and a recommended protocol covering screening cadence and modifiable risk-factor changes.

The underlying technology stack is not disclosed. Risk-modeling products in this category typically combine validated epidemiological models with proprietary weighting layers and a software UX. There is no GitHub presence, no developer documentation, and no published validation study. The product URL, app-dev.catchbio.com, is a development subdomain [Catch Bio].

Data Accuracy: ORANGE -- Product description triangulated across three independent listings, but no independent product review, demo writeup, or technical disclosure is available; tech stack is undisclosed.

Market Research and Opportunity

Catch Bio sits in the consumer cancer-prevention segment of healthtech, a category that overlaps with clinical cancer screening, longevity and preventive medicine memberships, and consumer genetic and biomarker testing. The endorsement from the Kahn Longevity Center situates Catch within the longevity-clinic ecosystem that has expanded alongside players like Function Health, Superpower, and Ezra [Kahn Longevity Center].

Demand drivers include the gap between standard age-based screening guidelines and a personalized, risk-stratified protocol [Kahn Longevity Center]. The f4.fund profile emphasizes the combination of risk factors and biomarkers as the input layer [f4.fund].

Sizing reference	Value
Catch Bio seed raise	$2,000,000
Catch Bio founding year	2023

Data Accuracy: ORANGE -- Company-level figures confirmed; market-level sizing is directional and drawn from analogous categories rather than a Catch Bio-specific third-party report.

Who Else Is Fighting for This

Catch Bio is positioned as a software-first cancer risk platform. The competitive map splits into three buckets: full-stack early-detection diagnostic companies (e.g., MCED blood-test providers), longevity-membership platforms that bundle broad biomarker panels with concierge interpretation, and the legacy standard clinical pathway.

Catch's edge is focus. By concentrating on cancer specifically, the company can build a deeper risk model and a sharper consumer message [Crunchbase] [f4.fund]. Whether this edge is durable depends on a proprietary data layer and distribution lock-in. The company is exposed on the brand and trust axis; a $2.0 million seed does not buy a national consumer brand, suggesting reliance on clinical-partner distribution to scale.

Opportunity

The largest plausible outcome for Catch is becoming the default risk-stratification layer for consumer cancer prevention: the software that sits between a person's biomarker and history data on one side and the screening, behavior, and biomarker recommendations on the other [Crunchbase] [f4.fund].

Scenario	What happens	Catalyst
Clinic-embedded risk layer	Catch becomes the cancer module inside longevity and preventive clinics	Additional named clinic partners
Direct-to-consumer subscription	Catch builds a self-pay membership around an annual updated cancer risk plan	Demonstrated cohort with retention metrics
Employer or payer channel	A self-insured employer or progressive payer contracts Catch as a covered benefit	Pilot study showing increased screening adherence

Data Accuracy: ORANGE -- Opportunity framing is grounded in cited product positioning and one named clinical endorsement; scale scenarios are explicitly labeled as scenarios rather than forecasts.

Sources

1. [PitchBook] Catch Bio 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/711218-71
2. [Crunchbase] Catch Bio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/catch-bio
3. [f4.fund] Catch Bio - Healthcare & Digital Health | https://f4.fund/startups/catchbio
4. [Kahn Longevity Center] CATCH BIO: The World's First Cancer Prevention Platform | https://www.kahnlongevitycenter.com/blog/catch-bio-the-worlds-first-cancer-prevention-platform
5. [Catch Bio] Catch Bio product site | https://app-dev.catchbio.com/
6. [formds.com, Jan 2025] Catch Bio, Inc. - fund raising filing | https://formds.com/issuers/catch-bio-inc
7. [Crunchbase] Seed Round - Catch Bio | https://www.crunchbase.com/funding_round/catch-bio-seed--11681966
8. [teeming.ai] Catch Bio | https://teeming.ai/c/catch-bio/d3d072e7-50e0-403e-84d5-6df871b2490d